Experts Perspectives: Navigating Newly Diagnosed MM to Early Relapse - Episode 9

Insights from IMS 2024 on Counseling Patients with Multiple Myeloma about CAR T-cell Therapy and Connecting to Referral Centers

November 15, 2024

Ajay Chari, MD, Noopur S. Raje, MD, Adriana Rossi, MD, Weill Cornell Medical College, Natalie Callander, MD, Tom Martin, MD

Panelists discuss how community providers can implement strategies and utilize resources to effectively connect patients to referral centers for chimeric antigen receptor T-cell therapy, while addressing how to initiate conversations about the therapy and counsel patients regarding potential adverse events.

Video Player is loading.

Current Time 0:00

Duration 0:00

Loaded: 0%

Stream Type LIVE

Remaining Time 0:00

EP. 1: Transplant Eligible, Newly Diagnosed Multiple Myeloma: PERSEUS & CASSIOPEIA Study Updates

EP. 2: Quadruplet Induction Regimen in Newly Diagnosed Multiple Myeloma

EP. 3: Transplant-ineligible Patients with Newly Diagnosed Multiple Myeloma: CEPHEUS, IMROZ, and BENEFIT Studies

EP. 4: MRD Negativity as a Trial Outcome and Its Use in Clinical Practice

EP. 5: Use of CAR T-cell Therapies for Early Relapse Multiple Myeloma

EP. 6: Considerations for Triplet or Quadruplet Regimens in Transplant-ineligible Patients with Newly Diagnosed Multiple Myeloma

EP. 7: Considerations for Use of CAR T-cell Therapy in Multiple Myeloma

EP. 8: CAR T-cell Therapies for Multiple Myeloma: KarMMa-3 and CARTITUDE-4 Study Updates at IMS 2024

Now Viewing

EP. 9: Insights from IMS 2024 on Counseling Patients with Multiple Myeloma about CAR T-cell Therapy and Connecting to Referral Centers

EP. 10: Importance of Early Referral for CAR T-cell Therapy in Multiple Myeloma and Patient Quality of Life

Dr Ajai Chari to Dr Callander: What are some strategies or potential resources for community providers to connect patients to referral centers?

Resource Link:

Ailawadhi S et al, Clin Lymphoma Myeloma Leuk 2024. Optimizing CAR T in MM: Clinical Pearls from Expert Roundtable.

Dr Ajai Chari to Dr Raje: How do you initiate the conversation about chimeric antigen receptor (CAR) T-cell therapy? What do you counsel or share with your patient when explaining CAR T?